BRCA1 and ovarian serous adenocarcinoma: Moreover, HR-proficient tumors showed a lower PD-L1 expression on the surface of intraepithelial and peritumoral immune cells compared to the BRCA1/2-mutated tumors, supporting a link between BRCA1/2-mutation status, immunogenicity, and improved survival in high grade serous ovarian cancer [64].